Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
NCT ID: NCT04535882
Last Updated: 2025-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
125 participants
OBSERVATIONAL
2020-10-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Alcohol Liver Disease
NCT07284862
Frequency and Risk Factors for Autoimmune Disorders and Rheumatic Manifestations in Egyptian Patients With IBD
NCT05771363
CRP /albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients
NCT06750315
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
NCT00517101
Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis
NCT06869590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CD patients whose CDAI \>150 were divided into the active CD group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serum leucine-rich alpha-2 glycoprotein (LRG) levels
Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* acute or chronic renal failure
* chronic heart diseases
* liver cirrhosis
* cancer
* acute or chronic infections
* ischemic colitis
* infectious colitis
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Showa Inan General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Akira Horiuchi
Chief
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Showa Inan General Hospital
Komagane, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LRG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.